thought call amgen find
strength base busi biosimilar
kra still hot topic convers
strong beat rais quarter driven partli base busi resili
biosimilar out-performance therebi rais tp amgen base
busi continu show strength even face encroach biosimilar although
weak asset face competit neulasta sensipar clearli
evid howev growth biosimilar franchis significantli outpac
expect quarter also suggest street mis-model franchis
highlight strategi revenu diversif could pay offparticularli
recent us launch ad uptak europ alreadi strong
kanjinti herceptin biosimilar amjevita humira addit us sale mvasi
avastin kanjinti launch could layer addit revenu support base busi
asset face biosimilar competit could also see near-term revenu compani
remicad biosimilar abp potenti fda approv eventu abp
rituxan biosimilar biosimilar franchis could defens moat
broader context drug price legisl could becom increasingli relev head
pipelin new data surpris given recent world lung
esmo updat rather broader discuss futur program next
step subsequ data expect done kra realli
need break indic compani plan look close move drug earlier
line therapi along explor role monotherapi agent combin
trial oncolog asset bcma hle data expect
previous thought could see updat dec still head balanc
continu like set-up note increment otezla revenu could help
solidifi revenu ep growth trajectori yet add model
expect deal close still think consensu reason
model updates/risk ep updat due revis revenu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
inc biotechnolog compani engag discoveri
develop manufactur market human therapeut
blue sky scenario assum tvgr better current
assumpt base-busi greater
current forecast assum greater expect growth
biosimilar franchis slower expect declin base
busi also assum posit data readout pipelin asset
regulatori approv abp abp
base busi sale poorer growth profil biosimilar
busi key pipelin asset assum slower expect
growth biosimilar franchis regulatori headwind drug
approv ip litig scenario assum lose patent
litig soliri enbrel also assum neg data readout
pipelin asset
 close
pipelin updat kra inhibitor phase nsclc monotherapi
continu enrol patient meanwhil initi cohort colorect cancer patient
enrol phase monotherapi studi target dose next clinic updat
oncolog asset bcma hle data expect
larg expect potenti
look franchis tezepelumab data expect late phase studi
adult adolesc sever asthma enrol complet recent move
biosimilar bla submiss abp rituxan biosimilar expect broadli
speak announc plan end neurosci research earli develop
program base challeng develop drug neurolog space
model adjust made adjust core commerci portfolio reflect
current revenu trajectori guidanc rais updat fy revenu
estim non-gaap ep
increas expect enbrel slightli base better expect revenu
decreas estim neulasta given faster near-term eros
biosimilar also ad eu sale even given posit chmp opinion per
manag increas oper expens absolut basi figur
amgen inc revenu incom dilut charl martineau pm univers toronto octob
valuat use wacc termin valu growth rate project
fulli dilut share experienc commerci regulatori
organ support diversifi portfolio product domest intern market
believ broad portfolio track record execut lower risk
achiev forecast incorpor view model
dcf analysi base sotp dcf primarili driven valuat sale base
busi valu biosimilar aimovig tezepelumab
even valu revenu combin
combin unalloc corpor expens net debt
sotp dcf valu
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
